210 related articles for article (PubMed ID: 18065800)
1. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
Zhou H; Tan KC; Shiu SW; Wong Y
Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
Li C; Gu Q
Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
[TBL] [Abstract][Full Text] [Related]
3. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
[TBL] [Abstract][Full Text] [Related]
5. [The total antioxidant capacity and low-molecular antioxidant concentration in plasma of type-2 diabetes patients with different stage of metabolic compensation and concomitant diabetic nephropathy].
Błaszczak R; Kujawski K; Kedziora-Kornatowska K; Kornatowski T; Kedziora J; Szadujkis-Szadurski L; Markuszewski L; Rysz J; Ertel D; Olszewski R
Pol Merkur Lekarski; 2005 Jan; 18(103):29-32. PubMed ID: 15859542
[TBL] [Abstract][Full Text] [Related]
6. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
Bansal S; Chawla D; Siddarth M; Banerjee BD; Madhu SV; Tripathi AK
Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
[TBL] [Abstract][Full Text] [Related]
7. A novel advanced glycation index and its association with diabetes and microangiopathy.
Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycosylation end products in patients with diabetic nephropathy.
Makita Z; Radoff S; Rayfield EJ; Yang Z; Skolnik E; Delaney V; Friedman EA; Cerami A; Vlassara H
N Engl J Med; 1991 Sep; 325(12):836-42. PubMed ID: 1875967
[TBL] [Abstract][Full Text] [Related]
9. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
[TBL] [Abstract][Full Text] [Related]
10. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
Jornayvaz FR; Brulhart-Meynet MC; James RW
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):613-9. PubMed ID: 19201174
[TBL] [Abstract][Full Text] [Related]
11. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy.
Zhou H; Tan KC; Shiu SW; Wong Y
Diabetes Metab Res Rev; 2008; 24(8):617-23. PubMed ID: 18802933
[TBL] [Abstract][Full Text] [Related]
12. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
Rosenblat M; Karry R; Aviram M
Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
[TBL] [Abstract][Full Text] [Related]
14. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Voorbij HA; Sluiter WJ; van Tol A
Eur J Clin Invest; 2009 Mar; 39(3):200-3. PubMed ID: 19260949
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
16. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients.
Aslan M; Sabuncu T; Kocyigit A; Celik H; Selek S
Nutr Metab Cardiovasc Dis; 2007 Dec; 17(10):734-40. PubMed ID: 17321120
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy.
Chabroux S; Canouï-Poitrine F; Reffet S; Mills-Joncour G; Morelon E; Colin C; Thivolet C
Diabetes Metab; 2010 Apr; 36(2):152-7. PubMed ID: 20137994
[TBL] [Abstract][Full Text] [Related]
18. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.
Piwowar A; Knapik-Kordecka M; Szczecińska J; Warwas M
Diabetes Metab Res Rev; 2008 Oct; 24(7):549-53. PubMed ID: 18613218
[TBL] [Abstract][Full Text] [Related]
19. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
20. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.
Kappelle PJ; de Boer JF; Perton FG; Annema W; de Vries R; Dullaart RP; Tietge UJ
Eur J Clin Invest; 2012 May; 42(5):487-95. PubMed ID: 21955281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
